Skip to main content

Table 2 Estimated GFR (eGFR) for patients with eGFR values at baseline and month 12

From: Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial

 

High ferritin FCM (n = 97)

Low ferritin FCM (n = 89)

Oral iron (n = 167)

eGFR at baseline (MDRD), mL/min/1.73 m2

   

 Mean (SD)

34.9 (11.3)

32.8 (10.8)

34.2 (12.3)

 ≥ 60, n (%)

1 (1.0)

1 (1.1)

3 (1.8)

 30 to <60, n (%)

62 (63.9)

51 (57.3)

101 (60.5)

 15 to <30, n (%)

34 (35.1)

37 (41.6)

60 (35.9)

 < 15, n (%)

0

0

3 (1.8)

eGFR at month 12 (MDRD), mL/min/1.73 m2

   

 Mean (SD)

35.6 (13.8)

32.1 (12.7)

33.4 (14.5)

 ≥ 60, n (%)

7 (7.2)

4 (4.5)

7 (4.2)

 30 to <60, n (%)

54 (55.7)

40 (44.9)

83 (49.7)

 15 to <30, n (%)

32 (33.0)

39 (43.8)

65 (38.9)

 < 15, n (%)

4 (4.1)

6 (6.7)

12 (7.2)

Change from baseline to month 12, LS mean (SE) (MDRD), mL/min/1.73 m2

0.7 (0.9)

-0.9 (0.9)

-0.9 (0.7)

p value for change vs oral irona

0.15

0.99

Reference

Relative change from baseline to month 12, LS mean (SE) (MDRD), %

3.1 (2.6)

-2.4 (2.7)

-2.2 (2.0)

p value for change vs oral irona

0.098

0.95

Reference

eGFR (CKD-EPI) mL/min/1.73 m2

n = 82

n = 68

n = 137

 Mean (SD) at baseline

33.5 (11.9)

32.0 (11.8)

32.5 (13.4)

 Mean (SD) at month 12

34.8 (13.1)

31.1 (13.5)

31.0 (14.8)

 Change, LS mean (SE), mL/min/1.73 m2

1.3 (1.0)

-1.2 (1.0)

-1.7 (0.7)

p value for change vs oral irona

0.012

0.68

Reference

  1. eGFR was estimated by the MDRD-4 equation [27] at the local laboratory
  2. CI confidence interval, CKD-EPI Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), eGFR estimated GFR, FCM ferric carboxymaltose, LS least squares, MDRD Modification of Diet in Renal Disease, SE standard error
  3. aAnalysis of covariance analysis based on least square mean values, using repeated measures